查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1802965

全球 AR恐惧症治疗市场：2032 年预测 - 按恐惧症类型、成分、部署方法、最终用户和地区进行分析

AR Phobia Treatment Market Forecasts to 2032 - Global Analysis By Phobia Type, Component, Deployment Mode, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球 AR恐惧症治疗市场预计在 2025 年将达到 1.657 亿美元，到 2032 年将达到 5.406 亿美元，预测期内的复合年增长率为 18.4%。

扩增实境(AR)恐惧症疗法是一种新颖的治疗方法，它利用身临其境型AR 技术，帮助患者在可控的互动环境中面对和应对特定的恐惧症。透过 AR 应用和设备模拟逼真的恐惧场景，患者可以安全、可自订且经济高效的方式接受分级暴露疗法。这种方法提高了患者的参与度，并减少了传统疗法的局限性，使其在行为健康干预领域越来越受欢迎。

根据美国心理健康研究所（NIMH）的数据，估计有 12.5% 的美国成年人在生命中的某个时刻会经历特定的恐惧症。

焦虑症和恐惧症盛行率上升

焦虑症和特定恐惧症在全球范围内的日益普及是这一市场的主要驱动力。盛行率的上升扩大了可及的患者群体，并直接刺激了对创新且便捷的治疗方法（例如基于AR的暴露疗法）的需求。此外，人们日益增长的心理健康意识正在将这些疾病非人格化，并鼓励人们寻求治疗。此外，AR在创建可控且身临其境型的治疗环境方面已被证实有效，使其成为优于传统方法的替代方案，并促使其被临床医生和医疗保健机构广泛采用。

实施成本高

AR头戴装置的高单位成本以及创建经临床检验的治疗内容的费用限制了其在私人诊所和小型诊所的普及。治疗师需要接受专业培训，这进一步增加了整体拥有成本。这一经济障碍可能会减缓其普及速度，尤其是在价格敏感型市场和新兴市场，并将市场发展限制在资金充足的营运商手中。

扩展到家庭护理和行动医疗应用

开发与行动医疗(行动医疗 ) 应用整合的家庭治疗解决方案蕴含着巨大的商机。这项扩展将使治疗的可近性更加民主化，并帮助患者克服地理和时间安排的障碍。远端监控功能使临床医生能够即时监督治疗进展并虚拟调整治疗通讯协定。此外，智慧型手机和价格实惠的扩增实境/虚拟实境 (AR/VR) 配件的广泛普及，为提供治疗内容、开闢新的收入来源以及促进更持续、以患者为中心的护理模式，创造了一个庞大且可扩展的平台。

资料隐私和安全问题

作业系统是网路攻击的热门目标，因为它们会收集高度私密的生物特征和效能数据。一旦发生资料洩露，可能会严重损害医疗服务提供者的声誉，并削弱患者的信任。此外，遵守复杂且不断发展的全球医疗资料法规（例如《健康保险流通与责任法案》(HIPAA) 和《一般资料保护规范》(GDPR)），会增加合规负担和营运复杂性，从而可能阻碍医疗服务提供者和病患的投资和采用。

COVID-19的影响：

新冠疫情显着加速了AR恐惧症治疗市场的发展。封锁和保持社交距离的规定扰乱了传统的面对面治疗，迫切需要远距心理健康解决方案。这推动了远端医疗和数位治疗方法的应用，包括基于AR的暴露疗法，这些疗法可以远端进行。此外，疫情期间人们对心理健康的关注度不断提高，也提高了人们对此类创新治疗方法的认知和接受度，为疫情后的市场发展提供了持续的动力。

预测期内恐惧症细分市场预计将成为最大的市场

由于全球恐惧症的盛行率高，且扩增实境（AR）技术在其治疗中具有出色的适用性，预计在预测期内，恐恐惧症领域将占据最大的市场占有率。 AR技术的独特之处在于，它能够高度逼真地模拟高海拔环境，且强度可控，使其成为分级暴露疗法的基础。此外，其用于模拟高度变化的清晰且可测量的参数使其成为临床应用的理想选择，深受治疗师和患者的青睐。

预计在预测期内，云端基础的部分将以最高的复合年增长率成长。

预计在预测期内，云端基础的细分市场将实现最高成长率，这得益于人们对扩充性、灵活且经济高效的解决方案的日益偏好，这些解决方案允许患者和医疗保健提供者远端存取治疗平台。云端基础的系统可与虚拟和扩增实境工具无缝集成，从而实现个人化治疗和即时进度追踪。此外，远端医疗服务的日益普及、互联网普及率的不断提高以及对远距心理健康支持的需求也推动了这一趋势。这些优势使云端基础的细分市场成为增强现实恐惧症治疗解决方案的可近性、效率和整体应用的关键驱动力。

比最大的地区

在预测期内，北美预计将占据最大的市场占有率，这得益于其先进的医疗基础设施、高昂的医疗成本以及对创新数位医疗技术的早期采用。该地区领先的市场参与者以及对心理健康的浓厚兴趣将进一步推动成长。此外，支持性的法律规范和对数位疗法的优惠报销方案正在推动医疗服务提供者的采用和患者的可及性，从而巩固北美作为主要收益地区的地位。

复合年增长率最高的地区：

预计亚太地区将在预测期内实现最高的复合年增长率，这得益于其庞大的患者群体、日益增长的精神健康意识以及医疗保健可及性的改善。快速的数位化、不断提升的智慧型手机普及率以及医疗IT基础设施投资的不断增加，为行动医疗和基于扩增实境（AR）的解决方案创造了肥沃的土壤。此外，焦虑症日益加重的负担以及专注于数位疗法的新兴企业的兴起，带来了巨大的未开发潜力，使该市场成为成长最快的市场。

成分

  • 软体
  • 硬体
  • 服务

免费客製化服务

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 市场机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

5. 全球 AR恐惧症治疗市场（按恐惧症类型）

  • 动物恐惧症
  • 恐惧症高症
  • 言语恐惧症
  • 飞行恐惧症
  • 恐惧症
  • 雷声恐惧症
  • 恐惧症
  • 其他类型的恐惧症

6. 全球 AR恐惧症治疗市场（按组成部分）

  • 软体
    • AR内容和应用程式
    • 平台/管理软体
  • 硬体
    • 头戴式显示器 (HMD) 和智慧眼镜
    • 智慧型手机和平板电脑
    • 感测器追踪器
  • 服务
    • 整合和部署
    • 支援和维护
    • 培训和咨询

7. 全球 AR恐惧症治疗市场（依部署方式）

  • 本地
  • 云端基础

8. 全球 AR恐惧症治疗市场（按最终用户）

  • 医院和诊所
  • 治疗与咨商中心
  • 家庭用户/患者
  • 研究和学术机构

9. 全球 AR恐惧症治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Limbix
  • Psious
  • BehaVR
  • XRHealth
  • Oxford VR
  • AppliedVR
  • Sanofi
  • Teva Pharmaceuticals
  • Johnson & Johnson
  • Novartis
  • Biogen
  • Pear Therapeutics
  • CognifiSense
  • Virtually Better
  • Mimerse
Product Code: SMRC30491

According to Stratistics MRC, the Global AR Phobia Treatment Market is accounted for $165.7 million in 2025 and is expected to reach $540.6 million by 2032 growing at a CAGR of 18.4% during the forecast period. Augmented reality (AR) phobia treatment is an emerging therapeutic approach that leverages immersive AR technologies to help individuals confront and manage specific phobias in controlled, interactive environments. By simulating realistic fear-inducing scenarios through AR applications and devices, patients can undergo gradual exposure therapy in a safe, customizable, and cost-effective manner. This method enhances engagement, reduces traditional therapy limitations, and is increasingly gaining traction in behavioral health interventions.

According to the National Institute of Mental Health (NIMH), an estimated 12.5% of U.S. adults experience a specific phobia at some time in their lives.

Market Dynamics:

Driver:

Rising prevalence of anxiety disorders and phobias

The increasing global incidence of anxiety disorders and specific phobias is a primary driver for this market. This rising prevalence expands the addressable patient population, directly catalyzing demand for innovative and accessible treatment modalities like AR-based exposure therapy. Additionally, growing mental health awareness destigmatizes these conditions, encouraging individuals to seek treatment. Moreover, the proven efficacy of AR in creating controlled, immersive therapeutic environments positions it as a superior alternative to traditional methods, compelling its adoption by clinicians and healthcare institutions.

Restraint:

High implementation costs

The high per-unit cost of AR headsets and the expense of creating clinically validated therapeutic content limit accessibility for individual practitioners and smaller clinics. The need for specialized training for therapists further increases the total cost of ownership. This financial barrier can slow down widespread adoption, particularly in price-sensitive markets and developing regions, potentially restricting market growth to well-funded entities.

Opportunity:

Expansion into home-based treatment and mHealth apps

A significant opportunity lies in the development of home-based treatment solutions integrated with mobile health (mHealth) applications. This expansion democratizes access to therapy, overcoming geographical and scheduling barriers for patients. Remote monitoring capabilities allow clinicians to oversee progress and adjust treatment protocols virtually. Moreover, the proliferation of smartphones and affordable AR/VR accessories creates a vast, scalable platform for delivering therapeutic content, opening new revenue streams and fostering a more continuous and patient-centric care model.

Threat:

Data privacy and security concerns

Operating systems collect highly personal biometric and performance data, making them attractive targets for cyberattacks. Breaches could lead to severe reputational damage for providers and erode patient trust. Moreover, navigating the complex, evolving landscape of global health data regulations, such as HIPAA and GDPR, adds compliance burdens and operational complexity, potentially deterring investment and adoption from both providers and patients.

Covid-19 Impact:

The Covid-19 pandemic significantly accelerated the AR phobia treatment market. Lockdowns and social distancing mandates disrupted traditional in-person therapy, creating an urgent need for remote, accessible mental health solutions. This catalyzed the adoption of telehealth and digital therapeutics, including AR-based exposure therapy, which could be administered remotely. Additionally, the heightened focus on mental wellness during the crisis increased awareness and acceptance of such innovative treatment modalities, providing a sustained boost to market development post-pandemic.

The acrophobia segment is expected to be the largest during the forecast period

The acrophobia segment is expected to account for the largest market share during the forecast period due to the high global prevalence of fear of heights and the exceptional suitability of AR for its treatment. AR technology is uniquely capable of simulating elevated environments with a high degree of realism and controllable intensity, which is fundamental for graduated exposure therapy. Additionally, the clear and measurable parameters for simulating height variations make it an ideal clinical application, driving its preference among therapists and patients alike, thereby securing its dominant market position.

The cloud-based segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cloud-based segment is predicted to witness the highest growth rate, driven by the rising preference for scalable, flexible, and cost-efficient solutions that allow patients and healthcare providers to access treatment platforms remotely. Cloud-based systems offer seamless integration with virtual reality and augmented reality tools, enabling personalized therapy and real-time progress tracking. Additionally, the increasing adoption of telehealth services, growing internet penetration, and demand for remote mental health support are accelerating this trend. These advantages position the cloud-based segment as a key driver in advancing accessibility, efficiency, and overall adoption of AR-based phobia treatment solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by its advanced healthcare infrastructure, high healthcare expenditure, and early adoption of innovative digital health technologies. The presence of leading market players and a strong focus on mental health in the region further propel growth. Additionally, supportive regulatory frameworks and favorable reimbursement scenarios for digital therapeutics encourage both provider adoption and patient access, consolidating North America's position as the dominant revenue-generating region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by a large patient population, increasing awareness of mental health disorders, and improving healthcare accessibility. Rapid digitalization, growing smartphone penetration, and rising investments in healthcare IT infrastructure create fertile ground for mHealth and AR-based solutions. Moreover, the increasing burden of anxiety disorders and a growing number of startups focusing on digital therapeutics present significant untapped potential, making it the fastest-growing market.

Key players in the market

Some of the key players in AR Phobia Treatment Market include Limbix, Psious, BehaVR, XRHealth, Oxford VR, AppliedVR, Sanofi, Teva Pharmaceuticals, Johnson & Johnson, Novartis, Biogen, Pear Therapeutics, CognifiSense, Virtually Better and Mimerse.

Key Developments:

In June 2025, Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced results from a study of treatment patterns among patients with tardive dyskinesia residing in long-term care facilities, highlighting a critical gap in TD diagnosis and treatment. Key results from the study revealed: Of the residents being treated with antipsychotic drugs, 5.6% had a diagnosis of extrapyramidal syndrome, - a broad term used to describe any drug-induced movement disorder with no wide-treating therapeutic option - while 1.1% had a specific diagnosis of TD.

In May 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced four data presentations for AUSTEDO(R) (deutetrabenazine) tablets and TV-46000/mdc-IRM. These data will be presented at the American Psychiatric Association (APA) Annual Meeting held May 21-25, 2022 in New Orleans, Louisiana, and again virtually June 7-10, 2022.

Phobia Types Covered:

  • Zoophobia
  • Acrophobia
  • Glossophobia
  • Aerophobia
  • Claustrophobia
  • Astraphobia
  • Trypanophobia
  • Other Phobia Types

Components:

  • Software
  • Hardware
  • Services

Deployment Modes Covered:

  • On-Premise
  • Cloud-Based

End Users Covered:

  • Hospitals and Clinics
  • Therapy and Counseling Centers
  • Home-based Users / Patients
  • Research and Academic Institutions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global AR Phobia Treatment Market, By Phobia Type

  • 5.1 Introduction
  • 5.2 Zoophobia
  • 5.3 Acrophobia
  • 5.4 Glossophobia
  • 5.5 Aerophobia
  • 5.6 Claustrophobia
  • 5.7 Astraphobia
  • 5.8 Trypanophobia
  • 5.9 Other Phobia Types

6 Global AR Phobia Treatment Market, By Component

  • 6.1 Introduction
  • 6.2 Software
    • 6.2.1 AR Content & Applications
    • 6.2.2 Platform/Management Software
  • 6.3 Hardware
    • 6.3.1 Head-Mounted Displays (HMDs) & Smart Glasses
    • 6.3.2 Smartphones & Tablets
    • 6.3.3 Sensors & Trackers
  • 6.4 Services
    • 6.4.1 Integration & Deployment
    • 6.4.2 Support & Maintenance
    • 6.4.3 Training & Consulting

7 Global AR Phobia Treatment Market, By Deployment Mode

  • 7.1 Introduction
  • 7.2 On-Premise
  • 7.3 Cloud-Based

8 Global AR Phobia Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Clinics
  • 8.3 Therapy and Counseling Centers
  • 8.4 Home-based Users / Patients
  • 8.5 Research and Academic Institutions

9 Global AR Phobia Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Limbix
  • 11.2 Psious
  • 11.3 BehaVR
  • 11.4 XRHealth
  • 11.5 Oxford VR
  • 11.6 AppliedVR
  • 11.7 Sanofi
  • 11.8 Teva Pharmaceuticals
  • 11.9 Johnson & Johnson
  • 11.10 Novartis
  • 11.11 Biogen
  • 11.12 Pear Therapeutics
  • 11.13 CognifiSense
  • 11.14 Virtually Better
  • 11.15 Mimerse

List of Tables

  • Table 1 Global AR Phobia Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global AR Phobia Treatment Market Outlook, By Phobia Type (2024-2032) ($MN)
  • Table 3 Global AR Phobia Treatment Market Outlook, By Zoophobia (2024-2032) ($MN)
  • Table 4 Global AR Phobia Treatment Market Outlook, By Acrophobia (2024-2032) ($MN)
  • Table 5 Global AR Phobia Treatment Market Outlook, By Glossophobia (2024-2032) ($MN)
  • Table 6 Global AR Phobia Treatment Market Outlook, By Aerophobia (2024-2032) ($MN)
  • Table 7 Global AR Phobia Treatment Market Outlook, By Claustrophobia (2024-2032) ($MN)
  • Table 8 Global AR Phobia Treatment Market Outlook, By Astraphobia (2024-2032) ($MN)
  • Table 9 Global AR Phobia Treatment Market Outlook, By Trypanophobia (2024-2032) ($MN)
  • Table 10 Global AR Phobia Treatment Market Outlook, By Other Phobia Types (2024-2032) ($MN)
  • Table 11 Global AR Phobia Treatment Market Outlook, By Component (2024-2032) ($MN)
  • Table 12 Global AR Phobia Treatment Market Outlook, By Software (2024-2032) ($MN)
  • Table 13 Global AR Phobia Treatment Market Outlook, By AR Content & Applications (2024-2032) ($MN)
  • Table 14 Global AR Phobia Treatment Market Outlook, By Platform/Management Software (2024-2032) ($MN)
  • Table 15 Global AR Phobia Treatment Market Outlook, By Hardware (2024-2032) ($MN)
  • Table 16 Global AR Phobia Treatment Market Outlook, By Head-Mounted Displays (HMDs) & Smart Glasses (2024-2032) ($MN)
  • Table 17 Global AR Phobia Treatment Market Outlook, By Smartphones & Tablets (2024-2032) ($MN)
  • Table 18 Global AR Phobia Treatment Market Outlook, By Sensors & Trackers (2024-2032) ($MN)
  • Table 19 Global AR Phobia Treatment Market Outlook, By Services (2024-2032) ($MN)
  • Table 20 Global AR Phobia Treatment Market Outlook, By Integration & Deployment (2024-2032) ($MN)
  • Table 21 Global AR Phobia Treatment Market Outlook, By Support & Maintenance (2024-2032) ($MN)
  • Table 22 Global AR Phobia Treatment Market Outlook, By Training & Consulting (2024-2032) ($MN)
  • Table 23 Global AR Phobia Treatment Market Outlook, By Deployment Mode (2024-2032) ($MN)
  • Table 24 Global AR Phobia Treatment Market Outlook, By On-Premise (2024-2032) ($MN)
  • Table 25 Global AR Phobia Treatment Market Outlook, By Cloud-Based (2024-2032) ($MN)
  • Table 26 Global AR Phobia Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global AR Phobia Treatment Market Outlook, By Hospitals and Clinics (2024-2032) ($MN)
  • Table 28 Global AR Phobia Treatment Market Outlook, By Therapy and Counseling Centers (2024-2032) ($MN)
  • Table 29 Global AR Phobia Treatment Market Outlook, By Home-based Users / Patients (2024-2032) ($MN)
  • Table 30 Global AR Phobia Treatment Market Outlook, By Research and Academic Institutions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.